EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

Mengyi Lao iD, Xiaozhen Zhang, Zejun Li, Kang Sun, Hanshen Yang, Sicheng Wang, Lihong He, Yan Chen, Hanjia Zhang, Jiatao Shi, Daqian Xu, Tingbo Liang iD und 1 weitere

Cancer Communications · 2025-08 · 45 (8) · 1010-1037

DOI: 10.1002/cac2.70038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 29.05.2025. Verfasst von Mengyi Lao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R.…. Hauptthemen laut MEDLINE: Sterol Regulatory Element Binding Protein 1, Proprotein Convertase 9, Pancreatic Neoplasms, Lipid Metabolism. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic cancer's aberrant lipid metabolism fuels cell growth, invasion, and metastasis, yet its impact on immune surveillance and immunotherapy is unclear. This study investigated how sterol regulatory element‐binding transcription factor 1 (SREBP1)‐driven lipid metabolism affects the tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC).

Methods

Clinical significance of SREBP1 was assessed in a PDAC cohort from China and The Cancer Genome Atlas (TCGA) cohorts. The in vitro mechanisms that SREBP1 regulated programmed cell death‐ligand 1 (PD‐L1) and proprotein convertase subtilisin/kexin type 9 (PCSK9) were investigated using immunofluorescence, flow cytometry, Western blotting, luciferase assays and chromatin immunoprecipitation. In vivo studies using PDAC‐bearing mice, humanized patient‐derived tumor xenograft (PDX) models, and autochthonous model of mutation (GEMM‐KTC) evaluated the efficacy and mechanisms of programmed death receptor 1 (PD‐1) antibodies and lipid inhibitors.

Results

Patients responding to anti‐PD‐1 therapy exhibited lower serum lipid levels than non‐responders. Targeting SREBP1 disrupted lipid metabolism, decelerated tumor growth, and boosted the efficacy of immunotherapy for PDAC. Mechanistically, SREBP1 directly bound the PD‐L1 promoter, suppressing its transcription. Meanwhile, PCSK9, a direct transcriptional target of SREBP1, modulated PD‐L1 levels via lysosomal degradation. Consequently, the combination of PCSK9‐neutralizing antibodies with PD‐1 monotherapy showed a robust antitumor effect in both humanized PDX and GEMM‐KTC models.

Conclusions

The SREBP1‐PCSK9 axis‐mediated lipid metabolism is crucial for triggering immune evasion and resistance to anti‐PD‐1. Targeting the SREBP1‐PCSK9 axis could potentially reverse PDAC's resistance to anti‐PD‐1 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sterol Regulatory Element Binding Protein 1Proprotein Convertase 9Pancreatic NeoplasmsLipid MetabolismCarcinoma, Pancreatic DuctalHumansAnimalsMiceB7-H1 AntigenTumor MicroenvironmentCell Line, TumorProgrammed Cell Death 1 ReceptorImmunotherapyXenograft Model Antitumor AssaysPCSK9 InhibitorsFemaleMaleImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

PCSK9PD‐1/PD‐L1Pancreatic ductal adenocarcinomaSREBP1immunochemotherapyimmunosuppressive tumor microenvironmentlipid metabolism

Substanzen

Sterol Regulatory Element Binding Protein 1Proprotein Convertase 9PCSK9 protein, humanSREBF1 protein, humanB7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorPCSK9 InhibitorsImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
  • Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
  • Cancer Center, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
  • Department of Breast Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.
  • Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.

ORCID-Profile: Mengyi Lao, Tingbo Liang, Xueli Bai

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lao, M., Zhang, X., Li, Z., Sun, K., Yang, H., Wang, S., He, L., Chen, Y., Zhang, H., Shi, J., Xu, D., Liang, T., & Bai, X. (2025). Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer Communications, 45(8), 1010-1037. https://doi.org/10.1002/cac2.70038

Vancouver

Lao M, Zhang X, Li Z, Sun K, Yang H, Wang S, et al. Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer Communications. 2025;45(8):1010-1037. doi:10.1002/cac2.70038

BibTeX
@article{Lao2025,
  author = {Lao, Mengyi and Zhang, Xiaozhen and Li, Zejun and Sun, Kang and Yang, Hanshen and Wang, Sicheng and He, Lihong and Chen, Yan and Zhang, Hanjia and Shi, Jiatao and Xu, Daqian and Liang, Tingbo and Bai, Xueli},
  title = {Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {8},
  pages = {1010--1037},
  doi = {10.1002/cac2.70038}
}
Kostenlos starten →